The FDA ob­jects to biotech bil­lion­aire Bob Dug­gan’s PhI­II plans — and he’s not budg­ing

Sum­mit Ther­a­peu­tics, the Cam­bridge, MA-based biotech run by bil­lion­aire in­vestor Bob Dug­gan, has found it­self in the FDA’s crosshairs.

Last month, Sum­mit an­nounced its in­tent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER